FLX475 CCR4 antagonist
FLX Bio, now RAPT Therapeutics
Animation created by KO Studios to demonstrate the MOA of FLX475, “a small molecule CCR4 antagonist designed to block the migration of Treg cells specifically into tumors, but not healthy tissues, without depleting Treg throughout the body, which we believe may decrease the likelihood of side effects. We are developing FLX475 for the treatment of a broad range of “charged” tumors, which represent cancer types we believe are most likely to respond to FLX475. In cancer, the secretion of certain chemokines from tumor cells and tumor-resident immune cells is responsible for recruitment of
immunosuppressive regulatory T cells (“Treg”) to tumor sites. Treg represent a dominant pathway for down regulating the immune response, and thus may limit the effectiveness of currently available therapies such as checkpoint inhibitors. Therefore, blocking the migration of Treg has the potential to restore naturally occurring antitumor immunity as well as to synergize with a variety of both conventional and immune-based therapies, such as radiation, chemotherapy, checkpoint inhibitors, immune stimulators and adoptive T cell therapy.” (see RAPT Therapeutics)